In this edition of The Practice Playbook, learn incident-to rules, Mohs coding limits, NPI liability, and how audits and whistleblowers trigger FCA cases.
Learn more about the in-depth topics covered in the July 2026 digital issue of Dermatology Times.
In July's letter from the editor in chief, Christopher Bunick, MD, PhD, breaks down why dermatology clinicians should be skilled in wound care.
In this Cosmetics Conundrums column, learn why the cosmeceutical vehicle drives 80% of skin care results, shaping feel, film, and active delivery for visible benefits.
RAD 2026 experts unpacked new IL-13, JAK, STAT6 and OX40 options, CHE and pediatric gaps, plus overlooked comorbidities shaping AD care.
Jane Yoo, MD, MPP, FAAD, shares expert tips to treat melasma in skin of color regarding sunscreen shades, hydroquinone breaks, TXA choices, and safer laser/peel decisions.
Our July issue tackles melanoma surgery challenges, melasma in skin of color, new bemotrizinol sunscreen, atopic dermatitis breakthroughs, and billing insights from Whitney Hovenic, MD, Joseph Gatti, DMSc, Rivkah Epstein, PA-C, and more.
New trends around cheeky swimwear and tanning myths are leading to rising rates of melanomas in sensitive areas; read July's cover story to learn more.
More than 35% of zasocitinib-treated patients reached complete skin clearance at week 16, with treatment curve separation emerging as early as week 8.
The FDA finalized the addition of bemotrizinol to the OTC sunscreen monograph, approving the broad-spectrum UV filter for use at concentrations up to 6% in adults and children 6 months or older.
Strong clinical observation and knowledge of disease variants are essential when advanced diagnostics are unavailable.
